【摘要】 目的 探讨瑞巴派特在早期胃癌术后溃疡患者中应用的效果。方法 选取2021年11月—2024年11月在烟台市烟台山医院接受治疗的早期胃癌术后溃疡患者150例作为研究对象，用随机数字表法分为单一治疗组和联合治疗组，每组75例。单一治疗组给予奥美拉唑治疗，联合治疗组在单一治疗组治疗的基础上加用瑞巴派特。2组均连续治疗4周。比较2组的临床疗效，治疗前、治疗4周后的溃疡愈合情况、胃黏膜形态学指标、胃肠激素、胃蛋白酶原、炎症指标及治疗期间的安全性。结果 联合治疗组的总有效率高于单一治疗组（92.00%vs. 76.00%, P<0.05）。治疗4周后，2组的瘢痕期占比均升高，且联合治疗组（94.67%）高于单一治疗组（81.33%）, P<0.05。治疗4周后，2组的各项胃黏膜形态学指标评分、血清胃动素（motilin, MTL）、胃泌素（gastrin,GAS）、胃蛋白酶原Ⅱ（pepsinogenⅡ，PG-Ⅱ）水平及炎症指标均降低，且联合治疗组均低于单一治疗组;2组的血清胃蛋白酶原Ⅰ（pepsinogenⅠ，PG-Ⅰ）水平均升高，且联合治疗组高于单一治疗组（P<0.05）。2组治疗期间不良反应发生率比较差异无统计学意义（P>0.05）。结论 瑞巴派特可有效改善早期胃癌术后溃疡患者的胃黏膜形态，调节患者胃肠激素及胃蛋白酶原水平，减轻患者的炎症反应，进一步促进溃疡愈合，进而提高临床疗效，且安全性良好。更多还原

【Abstract】 Objective To explore the efficacy of rabeprazole in patients with postoperative ulcers in early gastric cancer. Methods 150 patients with early gastric cancer postoperative ulcers who received treatment at Yantai Mountain Hospital of Yantai City from November 2021 to November 2024 were selected as the study subjects. The patients were divided into a single treatment group(75 cases) and a combination treatment group(75 cases) by random number table method. The single treatment group was given oeprazole, while the combination treatment group was given rabeprazole in addition to the single treatment group. Both groups received continuous treatment for 4 weeks. The clinical efficacy, including ulcer healing, gastric mucosal morphological indicators, gastrointestinal hormones, pepsinogen, and inflammatory indicators before and after 4 weeks of treatment, as well as safety during the treatment period of the 2 groups were compared. Results The total effective rate of the combination therapy group was higher than that of the single therapy group(92.00% vs. 76.00%, P<0.05). After 4 weeks of treatment, the proportion of scar stage in both groups increased, and the combined treatment group(94.67%) was higher than the single treatment group(81.33%), P<0.05. After 4 weeks of treatment, the scores of various gastric mucosal morphological indicators, the levels of serum motilin(MTL), gastrin(GAS), pepsinogen Ⅱ （PG-Ⅱ ）, and inflammatory indicators in both groups decreased, and the combined treatment group were lower than the single treatment group. The levels of serum pepsinogen Ⅱ （PG-Ⅱ） increased in both groups, and the combined treatment group was higher than the single treatment group(P<0.05). There was no significant difference in the incidence of adverse reactions between the 2 treatment groups(P>0.05). Conclusion Rabeprazole could effectively improve the morphology of gastric mucosa in patients with early gastric cancer postoperative ulcers, regulate the levels of gastrointestinal hormones and pepsinogen, reduce the inflammatory response of patients, further promote ulcer healing, and improve clinical efficacy with good safety.更多还原